JPWO2020084591A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020084591A5 JPWO2020084591A5 JP2021522350A JP2021522350A JPWO2020084591A5 JP WO2020084591 A5 JPWO2020084591 A5 JP WO2020084591A5 JP 2021522350 A JP2021522350 A JP 2021522350A JP 2021522350 A JP2021522350 A JP 2021522350A JP WO2020084591 A5 JPWO2020084591 A5 JP WO2020084591A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- seq
- biological sample
- dhx58
- parp9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 58
- 230000014509 gene expression Effects 0.000 claims description 54
- 239000012472 biological sample Substances 0.000 claims description 43
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims description 29
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 claims description 29
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims description 29
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims description 29
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims description 29
- 101001067396 Homo sapiens Phospholipid scramblase 1 Proteins 0.000 claims description 29
- 101000864662 Homo sapiens Probable ATP-dependent RNA helicase DHX58 Proteins 0.000 claims description 29
- 101000735459 Homo sapiens Protein mono-ADP-ribosyltransferase PARP9 Proteins 0.000 claims description 29
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims description 29
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 claims description 29
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims description 29
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims description 29
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims description 29
- 102100034627 Phospholipid scramblase 1 Human genes 0.000 claims description 29
- 102100034930 Protein mono-ADP-ribosyltransferase PARP9 Human genes 0.000 claims description 29
- 239000003112 inhibitor Substances 0.000 claims description 29
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 claims description 27
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 claims description 27
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 claims description 26
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 239000005557 antagonist Substances 0.000 claims description 20
- 230000001404 mediated effect Effects 0.000 claims description 20
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims description 8
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 206010025135 lupus erythematosus Diseases 0.000 claims description 8
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 6
- 206010058105 Neutrophilic dermatosis Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 201000001981 dermatomyositis Diseases 0.000 claims description 6
- 208000006132 lipodystrophy Diseases 0.000 claims description 6
- 208000005987 polymyositis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 102000002227 Interferon Type I Human genes 0.000 claims description 5
- 108010014726 Interferon Type I Proteins 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 4
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 4
- 206010020843 Hyperthermia Diseases 0.000 claims description 4
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 4
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 4
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 4
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000036031 hyperthermia Effects 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 101000641015 Homo sapiens Sterile alpha motif domain-containing protein 9 Proteins 0.000 claims description 2
- 102100034291 Sterile alpha motif domain-containing protein 9 Human genes 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- -1 HE R C5 Proteins 0.000 claims 3
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 2
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 238000011835 investigation Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024090820A JP2024119889A (ja) | 2018-10-26 | 2024-06-04 | Ｉ型インターフェロンシグネチャー及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751019P | 2018-10-26 | 2018-10-26 | |
| US62/751,019 | 2018-10-26 | ||
| PCT/IB2019/059178 WO2020084591A1 (en) | 2018-10-26 | 2019-10-25 | Type i interferon signatures and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090820A Division JP2024119889A (ja) | 2018-10-26 | 2024-06-04 | Ｉ型インターフェロンシグネチャー及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512796A JP2022512796A (ja) | 2022-02-07 |
| JPWO2020084591A5 true JPWO2020084591A5 (OSRAM) | 2022-11-01 |
Family
ID=70328348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522350A Withdrawn JP2022512796A (ja) | 2018-10-26 | 2019-10-25 | Ｉ型インターフェロンシグネチャー及び使用方法 |
| JP2024090820A Pending JP2024119889A (ja) | 2018-10-26 | 2024-06-04 | Ｉ型インターフェロンシグネチャー及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090820A Pending JP2024119889A (ja) | 2018-10-26 | 2024-06-04 | Ｉ型インターフェロンシグネチャー及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12009079B2 (OSRAM) |
| EP (1) | EP3873523A4 (OSRAM) |
| JP (2) | JP2022512796A (OSRAM) |
| KR (1) | KR20210084528A (OSRAM) |
| CN (1) | CN113692287A (OSRAM) |
| CA (1) | CA3117102A1 (OSRAM) |
| EA (1) | EA202191133A1 (OSRAM) |
| IL (1) | IL282479A (OSRAM) |
| MA (1) | MA54085A (OSRAM) |
| WO (1) | WO2020084591A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114836534A (zh) * | 2021-06-08 | 2022-08-02 | 中国医学科学院北京协和医院 | Samd9l基因突变作为i型干扰素病诊断的标志物及其应用 |
| AU2023339761A1 (en) | 2022-09-14 | 2025-03-20 | Viatris Asia Pacific Pte. Ltd. | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
| WO2024100139A1 (en) * | 2022-11-09 | 2024-05-16 | Merck Patent Gmbh | Use of ifn-i activity as a biomarker for tlr inhibitor treatment |
| KR20250145681A (ko) * | 2023-02-16 | 2025-10-13 | 알루미스 인크. | 피부과 장애를 치료하는 방법 |
| WO2024173764A1 (en) * | 2023-02-16 | 2024-08-22 | Alumis Inc. | Methods of treating hidradenitis suppurativa |
| WO2024201091A1 (en) * | 2023-03-27 | 2024-10-03 | Institut National de la Santé et de la Recherche Médicale | A gene signature for diagnosing stimulator of interferon genes (sting)-associated vasculopathy with onset in infancy (savi) |
| WO2024216160A1 (en) * | 2023-04-14 | 2024-10-17 | Arc Research Institute | Methods and compositions for using peli2 as a biomarker |
| CN117138038A (zh) * | 2023-09-21 | 2023-12-01 | 北京大学 | 一种预防、治疗或缓解椎体后纵韧带骨化症的药物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1904104T3 (da) * | 2005-07-08 | 2013-11-11 | Biogen Idec Inc | SP35-antistoffer og anvendelser heraf |
| EP2077858A4 (en) * | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| JP2010526107A (ja) * | 2007-05-03 | 2010-07-29 | メディミューン，エルエルシー | 自己免疫疾患の自己抗体マーカー |
| EP2419727A1 (en) * | 2009-04-14 | 2012-02-22 | Schering Corporation | Interferon-alfa sensitivity biomarkers |
| WO2012054284A2 (en) * | 2010-10-20 | 2012-04-26 | University Of Tennessee Research Foundation | Interferon gene signature and methods of use thereof |
| EP2701742A4 (en) * | 2011-04-26 | 2015-03-18 | Genentech Inc | COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES |
| BR112013030242A2 (pt) * | 2011-05-25 | 2016-12-06 | Medimmune Llc | método de tratamento de um distúrbio autoimune em um sujeito humano |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| US9493570B2 (en) * | 2012-06-13 | 2016-11-15 | Medimmune, Llc | Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies |
| CA2932787A1 (en) * | 2013-12-06 | 2015-06-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
| TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| US10689703B2 (en) * | 2015-04-27 | 2020-06-23 | National Jewish Health | Methods of identifying and treating subjects having acute respiratory distress syndrome |
| IL300274A (en) * | 2016-06-08 | 2023-04-01 | Abbvie Inc | Antibodies against B7–H3 and conjugates of drug and antibody |
| JP2022527542A (ja) * | 2019-04-04 | 2022-06-02 | ヤンセン バイオテツク，インコーポレーテツド | 抗ＩＦＮ－α／ω抗体の投与方法 |
-
2019
- 2019-10-25 EA EA202191133A patent/EA202191133A1/ru unknown
- 2019-10-25 JP JP2021522350A patent/JP2022512796A/ja not_active Withdrawn
- 2019-10-25 US US16/663,527 patent/US12009079B2/en active Active
- 2019-10-25 EP EP19874869.1A patent/EP3873523A4/en not_active Withdrawn
- 2019-10-25 MA MA054085A patent/MA54085A/fr unknown
- 2019-10-25 KR KR1020217015505A patent/KR20210084528A/ko not_active Withdrawn
- 2019-10-25 WO PCT/IB2019/059178 patent/WO2020084591A1/en not_active Ceased
- 2019-10-25 CN CN201980086249.XA patent/CN113692287A/zh active Pending
- 2019-10-25 CA CA3117102A patent/CA3117102A1/en active Pending
-
2021
- 2021-04-20 IL IL282479A patent/IL282479A/en unknown
-
2024
- 2024-06-04 JP JP2024090820A patent/JP2024119889A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012340624B2 (en) | Methods of treatment using an antibody against interferon gamma | |
| AU2008247398B2 (en) | Interferon alpha-induced pharmacodynamic markers | |
| RU2014127178A (ru) | Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006 | |
| AU2009212216B2 (en) | Disease markers and uses thereof | |
| EP3052193B1 (en) | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare | |
| WO2011028933A1 (en) | Type 1 interferon diagnostic | |
| CN112654640B (zh) | 抗IL-1β的抗体、其药物组合物及其用途 | |
| JP2024119889A (ja) | Ｉ型インターフェロンシグネチャー及び使用方法 | |
| JPWO2020084591A5 (OSRAM) | ||
| JP2012522039A (ja) | アデニリルシクラーゼ結合タンパク質（ｃａｐ１）及び免疫調節の標的としてのその使用 | |
| US20220267270A1 (en) | Sting modulators, compositions, and methods of use | |
| TW202241945A (zh) | 類固醇節制 | |
| CN115667309A (zh) | 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病 | |
| JPWO2019220412A5 (OSRAM) | ||
| WO2015132241A1 (en) | Treatment of inflammatory diseases | |
| JPWO2020191041A5 (OSRAM) | ||
| JPWO2021113702A5 (OSRAM) | ||
| CN116425871A (zh) | 抗新冠病毒s蛋白人源化抗体及其应用 | |
| JP2019520355A (ja) | ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 | |
| US20240368084A1 (en) | Sting modulators, compositions, and methods of use | |
| WO2020233571A1 (zh) | 一种双特异性分子及其制备与用途 | |
| Lewis et al. | Yael Gernez1*, Mansi Narula2, Alma-Martina Cepika2, Juanita Valdes Camacho3, Elisabeth G. Hoyte1, Kirsten Mouradian2, Bertil Glader2, Deepika Singh4, Bindu Sathi5, Latha Rao5, Ana L. Tolin6, Kenneth I. Weinberg2 | |
| WO2021209902A1 (en) | Materials and methods for improved prediction of igg therapeutic protein exposure | |
| RU2020128543A (ru) | Терапевтические и диагностические способы для воспалительных заболеваний, опосредованных тучными клетками | |
| JPWO2021072116A5 (OSRAM) |